Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPARHT
2023-506486-60-01Phase 3Authorised
- Sponsor
- Oslo University Hospital
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in kidney failure comparing Forxiga with Placebo (2 arms). Primary endpoint: eGFR slope from week 2 to month 12. Planned start Apr 2022; status: authorised.
02
Drugs
dapagliflozin
03
Conditions
kidney failure
Beyond the preview
Go deeper on 2023-506486-60-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506486-60-01.